Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMD1 | P17707 | 3/20 | 0.73 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.67 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952218 | 1.00 | AMD1 (0.73) | AMD1EZH2DOT1LPRMT1DPP4 | |
| SCHEMBL15012484 | 1.00 | AMD1 (0.73) | AMD1EZH2DOT1LPRMT1DPP4 | |
| SCHEMBL1770049 | 0.94 | AMD1 (0.76) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL1770046 | 0.94 | AMD1 (0.76) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL10660872 | 0.89 | DOT1L (0.75) | AMD1EZH2DOT1LPRMT1AHCY | |
| SCHEMBL10668844 | 0.89 | AMD1 (0.67) | AMD1EZH2DOT1LPRMT1DPP4 | |
| SCHEMBL995958 | 0.89 | AMD1 (0.77) | AMD1EZH2DOT1LPRMT1DPP4 | |
| SCHEMBL13986400 | 0.89 | AMD1 (0.80) | AMD1EZH2DOT1LDPP4MEN1 | |
| SCHEMBL10664656 | 0.89 | AMD1 (0.69) | AMD1EZH2DOT1LPRMT1DPP4 | |
| Water SCHEMBL10664708 | 0.89 | AMD1 (0.76) | AMD1EZH2DOT1LPRMT1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220260583-A1 | CHEMOPROTEOMIC PROFILING OF PROTEIN ELECTROPHILIC AND OXIDATIVE POST-TRANSLATIONAL MODIFICATIONS | Zenagem, LLC | 2022-08-18 | — | — | US | disclosed |
| US-11226337-B2 | Chemoproteomic profiling of protein electrophilic and oxidative post-translational modifications | Zenagem, LLC (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190204336-A1 | CHEMOPROTEOMIC PROFILING OF PROTEIN ELECTROPHILIC AND OXIDATIVE POST-TRANSLATIONAL MODIFICATIONS | Zenagem, LLC | 2019-07-04 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-9867794-B2 | Regulation of osteopontin | PATHOLOGICA LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2665471-B1 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | PATHOLOGICA LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3228310-A1 | METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT | Pathologica LLC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2121586-B1 | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS | PATHOLOGICA LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080262092-A1 | REGULATION OF OSTEOPONTIN | PATHOLOGICA LLC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1667727-B1 | POLYAMINE-METAL CHELATOR CONJUGATES | UNIV FLORIDA (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080096974-A2 | Polyamine-Metal Chelator Conjugates | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20060211773-A1 | Polyamine-metal chelator conjugates | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1667727-A2 | POLYAMINE-METAL CHELATOR CONJUGATES | University of Florida Research Foundation, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005023310-A2 | POLYAMINE-METAL CHELATOR CONJUGATES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-5872104-A | BACTERICIDES AND RESISTANT BACTERIA WITH METHYLATION INHIBITORS | ORIDIGM CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
| US-4794174-A | ENZYME INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 1988-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262092-A1 | REGULATION OF OSTEOPONTIN | ALPP, CD68, ACP3 | AMD1 2332/4885EZH2 3180/4885DOT1L 4098/4885 |
| US-20190204336-A1 | CHEMOPROTEOMIC PROFILING OF PROTEIN ELECTROPHILIC AND OXIDATIVE POST-TRANSLATIONAL MODIFICATIONS | PTMS, CHAMP1, STUB1 | AMD1 1916/4885EZH2 1588/4885DOT1L 1026/4885 |
| US-11226337-B2 | Chemoproteomic profiling of protein electrophilic and oxidative post-translational modifications | PTMS, CHAMP1, STUB1 | AMD1 1916/4885EZH2 1588/4885DOT1L 1026/4885 |
| US-20060211773-A1 | Polyamine-metal chelator conjugates | SLC40A1, SLC7A1, CATSPER1 | AMD1 717/4885EZH2 2449/4885DOT1L 598/4885 |
| US-20220260583-A1 | CHEMOPROTEOMIC PROFILING OF PROTEIN ELECTROPHILIC AND OXIDATIVE POST-TRANSLATIONAL MODIFICATIONS | STUB1, PTMS, TMT1A | AMD1 2518/4885EZH2 1192/4885DOT1L 1018/4885 |
| US-20080096974-A2 | Polyamine-Metal Chelator Conjugates | SLC7A1, SLC40A1, SRM | AMD1 311/4885EZH2 2456/4885DOT1L 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.